Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Serra EG., Schwerd T., Moutsianas L., Cavounidis A., Fachal L., Pandey S., Kammermeier J., Croft NM., Posovszky C., Rodrigues A., Russell RK., Barakat F., Auth MKH., Heuschkel R., Zilbauer M., Fyderek K., Braegger C., Travis SP., Satsangi J., Parkes M., Thapar N., Ferry H., Matte JC., Gilmour KC., Wedrychowicz A., Sullivan P., Moore C., Sambrook J., Ouwehand W., Roberts D., Danesh J., Baeumler TA., Fulga TA., Carrami EM., Ahmed A., Wilson R., Barrett JC., Elkadri A., Griffiths AM., COLORS in IBD group investigators None., Oxford IBD cohort study investigators None., INTERVAL Study None., Swiss IBD cohort investigators None., UK IBD Genetics Consortium None., NIDDK IBD Genetics Consortium None., Snapper SB., Shah N., Muise AM., Wilson DC., Uhlig HH., Anderson CA.
Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exome-sequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA, SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo, pathogenic allele in CYBB. The mutation is present in ~70% of phagocytes and sufficient to result in defective bacterial handling but not life-threatening infections. Finally, we show that VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls (99 patients and 18,780 controls; P